Inovio Pharmaceuticals, Inc. (INO)
Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript
Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript
Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms
Inovio Pharmaceuticals NASDAQ: INO said its biologics license application for INO-3107, an investigational DNA medicine for recurrent respiratory papillomatosis, or RRP, remains under U.S. Food and Drug Administration review, with a target action date of Oct. 30.
Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP
Inovio Pharmaceuticals NASDAQ: INO is approaching an October 30 PDUFA date for INO-3107, its lead DNA medicine candidate for recurrent respiratory papillomatosis, or RRP, President and CEO Jacky Shea said during a Cantor Fitzgerald fireside chat.
Inovio Pharmaceuticals, Inc. (INO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Inovio Pharmaceuticals, Inc. (INO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Inovio Pharmaceuticals Q2 Earnings Call Highlights
Inovio Pharmaceuticals NASDAQ: INO said the U.S. Food and Drug Administration has completed several key steps in its review of the company's biologics license application for INO-3107, an investigational treatment for recurrent respiratory papillomatosis, or RRP, while the company continues preparations for a potential commercial launch.
Inovio Pharmaceuticals, Inc. (INO) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Inovio Pharmaceuticals, Inc. (INO) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Inovio Pharmaceuticals Shareholders Back Board as INO-3107 FDA Review Advances
Inovio Pharmaceuticals NASDAQ: INO shareholders approved all proposals presented at the company's 2026 annual meeting, including the election of eight directors and the ratification of Ernst & Young LLP as the company's independent registered public accounting firm for the year ending Dec. 31, 2026.
Inovio: All Eyes On INO-3107 As Binary FDA Decision Looms
Inovio Pharmaceuticals remains a high-risk, event-driven play, with the investment case dominated by the binary FDA decision for INO-3107 in October. Cost discipline has improved, with operating expenses down to $21.9M and cash projected to fund operations into 1Q27, reducing near-term dilution risk. INO-3107 offers a differentiated, patient-friendly profile versus PAPZIMEOS, targeting a potentially larger-than-expected RRP population and non-responders.
Inovio (INO) Loses 32.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Inovio (INO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Here's Why Inovio (INO) Looks Ripe for Bottom Fishing
Inovio (INO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Inovio Stock Up On Earnings, Pipeline Progress
Inovio Pharmaceuticals Inc (NASDAQ: INO) shares are trading higher on Friday morning after the company reported fourth-quarter results that topped Wall Street's loss estimate and highlighted progress on its lead DNA medicine candidate. Here's what investors need to know.
Inovio Pharmaceuticals, Inc. (INO) Q4 2025 Earnings Call Transcript
Inovio Pharmaceuticals, Inc. (INO) Q4 2025 Earnings Call Transcript
